Since PD1 inhibition alone demonstrated limited activity in AML [82], other researchers have evaluated the efficacy of PD-1 inhibitors in combination with ipilimumab or HMA such as azacytidine and decitabine in AML and MDS patients. Here, PDCD1 is linked to myelodysplastic syndrome.